相似文献
1
Prospective study of fecal colonization by extended-spectrum-beta-lactamase-producing Escherichia coli in neutropenic patients with cancer.
Antimicrob Agents Chemother. 2008 Nov;52(11):4187-90. doi: 10.1128/AAC.00367-08. Epub 2008 Sep 22.
2
Seagulls of the Berlengas natural reserve of Portugal as carriers of fecal Escherichia coli harboring CTX-M and TEM extended-spectrum beta-lactamases.
Appl Environ Microbiol. 2008 Dec;74(23):7439-41. doi: 10.1128/AEM.00949-08. Epub 2008 Oct 3.
3
[Analysis of antibiotic resistance and genotypes on extended spectrum β-lactamase and AmpC β-lactamase producing strains isolated from Uygur and Han newborns].
Zhonghua Yu Fang Yi Xue Za Zhi. 2011 Mar;45(3):217-24.
4
Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome.
J Antimicrob Chemother. 2010 Feb;65(2):333-41. doi: 10.1093/jac/dkp411. Epub 2009 Dec 3.
5
High prevalence of ESBL-producing Escherichia coli isolates among hemodialysis patients in Portugal: appearance of ST410 with the bla(CTX-M-14) gene.
Diagn Microbiol Infect Dis. 2012 Dec;74(4):423-5. doi: 10.1016/j.diagmicrobio.2012.08.017. Epub 2012 Sep 20.
6
CTX-M-producing Escherichia coli in a maternity ward: a likely community importation and evidence of mother-to-neonate transmission.
J Antimicrob Chemother. 2010 Jul;65(7):1368-71. doi: 10.1093/jac/dkq153. Epub 2010 May 13.
7
Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):355-60. doi: 10.1007/s10096-010-1093-x. Epub 2010 Oct 30.
8
Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control.
Clin Infect Dis. 2006 Jan 1;42(1):37-45. doi: 10.1086/498519. Epub 2005 Nov 29.
9
[Asymptomatic and simultaneous fecal carriage of two strains of Escherichia coli expressing CTX-M-1 and CTX-M-14 extended-spectrum betalactamases].
Med Mal Infect. 2012 Mar;42(3):133-4. doi: 10.1016/j.medmal.2012.01.009. Epub 2012 Mar 8.
10
Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
J Microbiol Immunol Infect. 2012 Jun;45(3):193-9. doi: 10.1016/j.jmii.2011.11.003. Epub 2012 May 12.
引用本文的文献
1
Carbapenem Versus Non-carbapenem Therapy in Hematology Patients: Extended-Spectrum Beta-Lactamase Positive Enterobacteriaceae Colonization Impact.
Cureus. 2024 Jul 1;16(7):e63570. doi: 10.7759/cureus.63570. eCollection 2024 Jul.
2
Colonization by Extended-Spectrum β-Lactamase-Producing Enterobacterales and Bacteremia in Hematopoietic Stem Cell Transplant Recipients.
Antibiotics (Basel). 2024 May 15;13(5):448. doi: 10.3390/antibiotics13050448.
3
Fecal Carriage of Extended-Spectrum β-Lactamase and Carbapenemase-Producing Enterobacteriaceae Among Oncology and Non-Oncology Patients at Jimma Medical Center in Ethiopia: A Comparative Cross-Sectional Study.
Cancer Manag Res. 2023 Nov 1;15:1217-1231. doi: 10.2147/CMAR.S422376. eCollection 2023.
4
Evaluation of antibiotic resistance, toxin-antitoxin systems, virulence factors, biofilm-forming strength and genetic linkage of Escherichia coli strains isolated from bloodstream infections of leukemia patients.
BMC Microbiol. 2023 Nov 4;23(1):327. doi: 10.1186/s12866-023-03081-8.
5
Comparison of the global prevalence and trend of human intestinal carriage of ESBL-producing between healthcare and community settings: a systematic review and meta-analysis.
JAC Antimicrob Resist. 2022 Jun 2;4(3):dlac048. doi: 10.1093/jacamr/dlac048. eCollection 2022 Jun.
6
spp. and colonization in neutropenic febrile children with cancer.
Germs. 2017 Jun 1;7(2):61-72. doi: 10.18683/germs.2017.1110. eCollection 2017 Jun.
7
The prevention and management of infections due to multidrug resistant organisms in haematology patients.
Br J Clin Pharmacol. 2015 Feb;79(2):195-207. doi: 10.1111/bcp.12310.
8
Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies.
Eur J Clin Microbiol Infect Dis. 2011 Mar;30(3):355-60. doi: 10.1007/s10096-010-1093-x. Epub 2010 Oct 30.
本文引用的文献
1
Molecular epidemiology of extended-spectrum beta-lactamases among Escherichia coli isolates collected in a Swedish hospital and its associated health care facilities from 2001 to 2006.
J Clin Microbiol. 2008 Feb;46(2):707-12. doi: 10.1128/JCM.01943-07. Epub 2007 Dec 19.
2
CTX-M: changing the face of ESBLs in Europe.
J Antimicrob Chemother. 2007 Feb;59(2):165-74. doi: 10.1093/jac/dkl483. Epub 2006 Dec 6.
3
Antibiotic coresistance in extended-spectrum-beta-lactamase-producing Enterobacteriaceae and in vitro activity of tigecycline.
Antimicrob Agents Chemother. 2006 Aug;50(8):2695-9. doi: 10.1128/AAC.00155-06.
4
Risk-factors for acquisition of extended-spectrum beta-lactamase-producing Escherichia coli among hospitalised patients.
Clin Microbiol Infect. 2006 Mar;12(3):279-84. doi: 10.1111/j.1469-0691.2005.01358.x.
5
Clinical and molecular epidemiology of extended-spectrum beta-lactamase-producing Escherichia coli as a cause of nosocomial infection or colonization: implications for control.
Clin Infect Dis. 2006 Jan 1;42(1):37-45. doi: 10.1086/498519. Epub 2005 Nov 29.
6
Surveillance of extended-spectrum beta-lactamases from clinical samples and faecal carriers in Barcelona, Spain.
J Antimicrob Chemother. 2005 Dec;56(6):1152-5. doi: 10.1093/jac/dki395. Epub 2005 Oct 21.
7
Extended-spectrum beta-lactamases: a clinical update.
Clin Microbiol Rev. 2005 Oct;18(4):657-86. doi: 10.1128/CMR.18.4.657-686.2005.
8
Emergence of Enterobacteriaceae producing extended-spectrum beta-lactamases (ESBLs) in the community.
J Antimicrob Chemother. 2005 Jul;56(1):52-9. doi: 10.1093/jac/dki166. Epub 2005 May 25.
9
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.
Antimicrob Agents Chemother. 2004 Dec;48(12):4574-81. doi: 10.1128/AAC.48.12.4574-4581.2004.
10
Dramatic increase in prevalence of fecal carriage of extended-spectrum beta-lactamase-producing Enterobacteriaceae during nonoutbreak situations in Spain.
J Clin Microbiol. 2004 Oct;42(10):4769-75. doi: 10.1128/JCM.42.10.4769-4775.2004.
Zotero 插件